Literature DB >> 17437820

Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy.

David E Kang1, Michaella M Maloney, George E Haleblian, W Patrick Springhart, Emily F Honeycutt, Eric L Eisenstein, Charles G Marguet, Glenn M Preminger.   

Abstract

PURPOSE: Percutaneous nephrolithotomy is a commonly used procedure for treatment of large or complex renal calculi. In some instances postoperative residual stone fragments are an unavoidable result. Yet to our knowledge no study has examined the impact of medical management on stone formation in patients with or without residual fragments following percutaneous nephrolithotomy. Thus, we have conducted the first investigation of aggressive medical management following percutaneous nephrolithotomy and its impact on stone formation rates in patients with and without residual fragments.
MATERIALS AND METHODS: A total of 70 patients who underwent percutaneous nephrolithotomy and received counseling regarding selective medical management following a comprehensive metabolic evaluation, were identified. Patients were placed into 4 groups following percutaneous nephrolithotomy, that is stone-free or residual fragments, who underwent or did not undergo medical therapy. New stone formation was assessed by spontaneous stone passage in the absence of residual stone fragments, stone passage without change in the number of residual fragments, surgical removal of newly formed stones, or appearance of new stones or increase in size of stone or fragments on abdominal radiographs. Stone remission rates were also calculated.
RESULTS: Selective medical therapy significantly decreased stone formation rates in the stone-free (0.67 stones per patient per year vs 0.02) and residual fragment groups (0.67 stones per patient per year vs 0.02) as determined by the Wilcoxon signed rank test (p<0.0001). Moreover, remission was observed in a higher proportion of patients in the medically treated stone-free and residual fragment groups (87% and 77%) when compared to the same groups without medical therapy (29% and 21%, chi-square test p<0.0001).
CONCLUSIONS: Our findings suggest that comprehensive metabolic evaluation and aggressive medical management can control active stone formation and growth in patients with or without residual stone fragments after percutaneous nephrolithotomy. Given the inherent morbidity and increased costs attendant with repeat procedures, medical management should be instituted in patients following percutaneous nephrolithotomy without regard to stone-free status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437820     DOI: 10.1016/j.juro.2007.01.061

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

Review 2.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

Review 3.  When (and how) to surgically treat asymptomatic renal stones.

Authors:  Zachariah G Goldsmith; Michael E Lipkin
Journal:  Nat Rev Urol       Date:  2012-03-27       Impact factor: 14.432

Review 4.  Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Bridget Sinnott
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

5.  Quantitative Prediction of Stone Fragility From Routine Dual Energy CT: Ex vivo proof of Feasibility.

Authors:  Andrea Ferrero; Juan C Montoya; Lisa E Vaughan; Alice E Huang; Ian O McKeag; Felicity T Enders; James C Williams; Cynthia H McCollough
Journal:  Acad Radiol       Date:  2016-10-04       Impact factor: 3.173

Review 6.  Residual fragments after percutaneous nephrolithotomy.

Authors:  Kaan Ozdedeli; Mete Cek
Journal:  Balkan Med J       Date:  2012-09-01       Impact factor: 2.021

7.  The use of a ureteral access sheath does not improve stone-free rate after ureteroscopy for upper urinary tract stones.

Authors:  Gaetan Berquet; Paul Prunel; Grégory Verhoest; Romain Mathieu; Karim Bensalah
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

8.  The effect of citrate replacement in hypocitraturic cases on the results of SWL: a preliminary prospective randomized study.

Authors:  Cemal Göktaş; Rahim Horuz; Oktay Akça; Cihangir A Cetinel; Onder Cangüven; Alper Kafkaslı; Selami Albayrak; Kemal Sarıca
Journal:  Int Urol Nephrol       Date:  2012-05-12       Impact factor: 2.370

9.  Correspondence between Ca²⁺ and calciuria, citrate level and pH of urine in pediatric urolithiasis.

Authors:  Tadeusz Porowski; Jan K Kirejczyk; Jerzy Konstantynowicz; Anna Kazberuk; Grzegorz Plonski; Anna Wasilewska; Norbert Laube
Journal:  Pediatr Nephrol       Date:  2013-02-03       Impact factor: 3.714

10.  Ureteroscopy-assisted retrograde nephrostomy for an obese patient.

Authors:  Takashi Kawahara; Junichi Matsuzaki; Yoshinobu Kubota
Journal:  Indian J Urol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.